A state-of-the-art laboratory and a breakthrough discovery are only the beginning of the journey.
Between a scientific discovery and a medicine reaching patients lies an entire value chain encompassing regulatory, business and investment processes. This is precisely where Polish science most often comes to a standstill.
In the latest episode of the WZ-ka z biznesem podcast, Katarzyna Buszkowska talks to Marta Winiarska, President of the Polish Union of Innovative Medical Biotechnology Companies BioInMed and co-creator of the Faculty’s new postgraduate programme, Management and Commercialisation of Life Science Research Projects.
Their conversation explores a pivotal moment for the Polish biotechnology sector.
After two decades of building the industry, Poland is—as our guest explains—on the verge of a major leap forward: the development of the first innovative medicine by a Polish company.
The episode addresses, among other topics:
🔹 where collaboration between academia and business breaks down—and why the problem lies in mindset rather than a lack of expertise;
🔹 why scientists need to learn how to entrust their “baby” to professionals with different roles and areas of expertise;
🔹 how to develop a pitch that will convince investors, using the example of the bionic pancreas;
🔹 what patient capital is and why the life sciences sector cannot develop without it.
The new postgraduate programme was created to equip scientists, managers and entrepreneurs with a shared language and a comprehensive understanding of the commercialisation process.
Find out more about the programme:https://wz.uw.edu.pl/en/candidate/postgraduate-programmes/scientific-projects-management-in-life-sciences/